Clinical Practice Guidelines for supplemental therapies and issues

Kidney International

Volumn 74, Issue SUPPL.110, 2008, Pages

  Klarenbach, Scott W ^a   Moist, Louise M ^b   Foley, Rob N ^c   Barrett, Brendan J ^d   Madore, Francois ^e   White, Colin T ^f   Culleton, Bruce F ^g   Tonelli, Marcello ^a   Manns, Braden J ^g  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^d MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^e HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ASCORBIC ACID; CARNITINE; DIALYSIS FLUID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NANDROLONE DECANOATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PENTOXIFYLLINE; PLACEBO; PYRIDOXINE; RECOMBINANT ERYTHROPOIETIN; TESTOSTERONE; ULTRAPURE DIALYSATE; ANTIANEMIC AGENT;

ACNE; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIALYSATE; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; HIRSUTISM; HUMAN; INJECTION SITE PAIN; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VIRILIZATION; ACUTE KIDNEY FAILURE; ARTICLE; CHRONIC KIDNEY FAILURE; EVIDENCE BASED MEDICINE; MEDICAL RESEARCH; RENAL REPLACEMENT THERAPY;

ANEMIA; BIOMEDICAL RESEARCH; EVIDENCE-BASED MEDICINE; HEMATINICS; HUMANS; KIDNEY FAILURE, ACUTE; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS;

EID: 53449087138     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.271     Document Type: Article

References (44)

1. Berns JS, Rudnick MR, Cohen RM. A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis. Clin Nephrol 1992; 37: 264-267.
2. Gaughan WJ, Liss KA, Dunn SR et al. A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. Am J Kidney Dis 1997; 30: 495-500.
3. Sheashaa H, Abdel-Razek W, El-Husseini A et al. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis. Nephron Clin Pract 2005; 99: c102-c106.
4. Brockenbrough AT, Dittrich MO, Page ST et al. Transdermal androgen therapy to augment EPO in the treatment of anemia of chronic renal disease. Am J Kidney Dis 2006; 47: 251-262.
5. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006; 47(Suppl 3): S1-S146.
6. Kletzmayr J, Mayer G, Legenstein E et al. Anemia and carnitine supplementation in hemodialyzed patients. Kidney Int Suppl 1999; 69: S93-S106.
7. Labonia WD. -Carnitine effects on anemia in hemodialyzed patients treated with erythropoietin. Am J Kidney Dis 1995; 26: 757-764.
8. Semeniuk J, Shalansky KF, Taylor N et al. Evaluation of the effect of intravenous L-carnitine on quality of life in chronic hemodialysis patients. Clin Nephrol 2000; 54: 470-477.
9. Steiber AL, Davis AT, Spry L et al. Carnitine treatment improved quality-of-life measure in a sample of Midwestern hemodialysis patients. JPEN J Parenter Enteral Nutr 2006; 30: 10-15.
10. Vaux EC, Taylor DJ, Altmann P et al. Effects of carnitine supplementation on muscle metabolism by the use of magnetic resonance spectroscopy and near-infrared spectroscopy in end-stage renal disease. Nephron Clin Pract 2004; 97: c41-c48.
11. Caruso U, Leone L, Cravotto E et al. Effects of L-carnitine on anemia in aged hemodialysis patients treated with recombinant human erythropoietin: a pilot study. Transplant 1998; 27: 498-506.
12. Hurot JM, Cucherat M, Haugh M et al. Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review. J Am Soc Nephrol 2002; 13: 708-714.
13. Deira J, Diego J, Martinez R et al. Comparative study of intravenous ascorbic acid versus low-dose desferroxamine in patients on hemodialysis with hyperferritinemia. J Nephrol 2003; 16: 703-709.
14. Giancaspro V, Nuzziello M, Pallotta G et al. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial. J Nephrol 2000; 13: 444-449.
15. Keven K, Kutlay S, Nergizoglu G et al. Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients. Am J Kidney Dis 2003; 41: 1233-1239.
16. Taji Y, Morimoto T, Okada K et al. Effects of intravenous ascorbic acid on erythropoiesis and quality of life in unselected hemodialysis patients. J Nephrol 2004; 17: 537-543.
17. Attallah N, Osman-Malik Y, Frinak S et al. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Am J Kidney Dis 2006; 47: 644-654.
18. Hsu PY, Lin CL, Yu CC et al. Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients - a prospective cross-over study. J Nephrol 2004; 17: 693-700.
19. Schiffl H, Lang SM, Bergner A. Ultrapure dialysate reduces dose of recombinant human erythropoietin. Nephron 1999; 83: 278-279.
20. Sitter T, Bergner A, Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant 2000; 15: 1207-1211.
21. Lamas JM, Alonso M, Sastre F et al. Ultrapure dialysate and inflammatory response in haemodialysis evaluated by darbepoetin requirements - a randomized study. Nephrol Dial Transplant 2006; 21: 2851-2858.
22. Walsh M, Culleton B, Tonelli M et al. A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism, and health-related quality of life. Kidney Int 2005; 67: 1500-1508.
23. Culleton BF, Walsh M, Klarenbach S et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. J Am Med Assoc 2007; 298: 1291-1299.
24. Sirken G, Kung SC, Raja R. Decreased erythropoietin requirements in maintenance hemodialysis patients with statin therapy. ASAIO J 2003; 49: 422-425.
25. Cooper A, Mikhail A, Lethbridge MW et al. Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. J Am Soc Nephrol 2004; 15: 1877-1882.
26. Weissgarten J, Modai D, Oz D et al. Vitamin B(6) therapy does not improve hematocrit in hemodialysis patients supplemented with iron and erythropoietin. Nephron 2001; 87: 328-332.
27. Kaysen GA, Muller HG, Ding J et al. Challenging the validity of the EPO index. Am J Kidney Dis 2006; 47: 166.
28. Gejyo F, Saito A, Akizawa T et al. 2004 Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients. Ther Apher Dial 2004; 8: 443-459.
29. Locatelli F, Aljama P, Barany P et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19(Suppl 2): ii1-ii47.
30. Pollock C, McMahon L. The CARI guidelines. Biochemical and haematological targets guidelines. Haemoglobin. Nephrology (Carlton) 2005; 10(Suppl 4): S108-S115.
31. Renal Association. Treatment of Adults and Children with Renal Failure: Standards and Audit Measures, 3rd edn. London, 2002.
32. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590.
33. Singh A, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2096.
34. Zhang Y, Thamer M, Stefanik K et al. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 2004; 44: 866-876.
35. Nemoto T, Yokota N, Keane WF et al. Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure. Kidney Int 2001; 59: 246-251.
36. Park J, Gage BF, Vijayan A. Use of EPO in critically ill patients with acute renal failure requiring renal replacement therapy. Am J Kidney Dis 2005; 46: 791-798.
37. Corwin HL, Gettinger A, Pearl RG et al. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. J Am Med Assoc 2002; 288: 2827-2835.
38. Corwin HL, Gettinger A, Rodriguez RM et al. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. Crit Care Med 1999; 27: 2346-2350.
39. Silver M, Corwin MJ, Bazan A et al. Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial. Crit Care Med 2006; 34: 2310-2316.
40. Corwin HL, Hebert P. Avoiding a blood transfusion: how much is it worth? Crit Care Med 2005; 33: 672-674.
41. Johnson DW, Pat B, Vesey DA et al. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int 2006; 69: 1806-1813.
42. Sharples EJ, Patel N, Brown P et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 2004; 15: 2115-2124.
43. Spandou E, Tsouchnikas I, Karkavelas G et al. Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/ reperfusion model. Nephrol Dial Transplant 2006; 21: 330-336.
44. Sharples EJ, Yaqoob MM. Erythropoietin and acute renal failure. Semin Nephrol 2006; 26: 325-331.